west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "钟国成" 2 results
  • 多发性骨髓瘤过继细胞免疫治疗的研究进展

    【摘要】 多发性骨髓瘤(multiple myeloma, MM)是严重威胁健康的恶性浆细胞疾病,主要的治疗方法是传统化学疗法,但其疗效有限,患者生活质量低,预后差。免疫治疗是一种新兴的有望在未来彻底消灭肿瘤细胞的治疗手段,过继细胞免疫治疗(adoptive cellular immunotherapy, ACI)更是经体内及体外都证实了具有强大的抗瘤作用。ACI与其他治疗手段的有机结合和合理安排将对MM的治疗带来新的曙光。现就目前开展的ACI治疗MM的前沿研究予以综述。

    Release date:2016-08-26 02:18 Export PDF Favorites Scan
  • Therapeutic Effect of Bortezomib Combined with Dexamethasone and Thalidomide Regimens on Aged Patients with Multiple Myeloma

    ObjectiveTo investigate the efficacy and safety of bortezomib combined with dexamethasone and thalidomide regimens on aged patients with multiple myeloma. MethodsA total of 166 multiple myeloma patients were selected between January 2009 and June 2013; all patients were assigned to regimens of T-VD or T-VAD named T-VD group or T-VAD group (with 25 patients in T-VD group and 29 in T-VAD group). Efficacies and toxicities were analyzed and compared after two cycles. ResultsOverall response rate (OR) in T-VD group was 84.0%; there was 6 patients achieved complete response (OR) or very good partial response (VGPR) (24.0%). However, Overall response rate (OR) in T-VAD group was 48.3%; there was only one patient achieved CR or VGPR (3.4%); significant difference between two groups was found (χ2=7.513, P<0.05). The major adverse reactions were debilitation, nausea, vomiting, myelo-suppression, cardiac toxicity, and peripheral neuropathy. There were highest incidence of nausea and vomiting in T-VAD group compared to T-VD group (χ2=5.794, P<0.05). ConclusionBortezomib combined with dexamethasone and thalidomide regimens is effective and safe, which can be widely used for aged patients with multiple myeloma.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content